Biofourmis hires two experienced pharma executives as it looks to accelerate its global expansion

August 26, 2019
Digital Transformation More...
by Nardev Ramanathan
Average importance

Biofourmis' announcement of two pharma veteran hires comes close on the heels of its partnership with the U.S. FDA and other major institutions to use digital therapeutics and wearables to study clinical endpoints in drug trials. Peter Braun and John Varaklis both bring a combined half a century of pharma experience in global strategy and clinical operations, respectively. Barely half a decade old, Biofourmis has shown rapid momentum in acquiring funding and forging strategic partnerships to validate its algorithms. Lux has shared the importance of strategic pharma partnerships, but strategic pharma hires also boost internal strategy to position digital therapeutics on equal footing with a traditional pharma product. 

For the original news article, click here .

Further Reading

Enterome and Takeda sign a strategic deal for microbiome-based therapeutics

News Commentary | October 25, 2018

Following on the heels of uBiome's Series C funding, French startup Enterome recently signed a deal with pharmaceutical company Takeda to further the development and commercialization of its drug lead "EB8018," targeting Crohn's disease. As a part of this deal, Enterome will receive an upfront ... Not part of subscription

Takeda looks to jump-start its AI drug development efforts with Numerate, a well-positioned start-up in the field

Case Study | June 05, 2018

Takeda Pharmaceutical is Japan's largest drug company, and, with more than $15 billion in annual revenues, is also among the largest in the world. Therapeutic focus areas for the company include neuroscience, gastroenterology, oncology, and vaccines, and the firm is continuing to try to build out ... Not part of subscription

AI for Drug Discovery

Technology | June 08, 2018

Using artificial intelligence to help accelerate drug discovery, screening, development, and related pharmaceutical research. Not part of subscription